Abstract
Background: It still remains unclear whether adaptive servo ventilation (ASV) improves cardiac function and prognosis of patients with heart failure (HF) and Cheyne-Stokes respiration (CSR). Methods: Sixty patients with HF and CSR (LVEF 38.7%, apnea hypopnea index 36.8 times/hr) were enrolled in this study: 23 patients treated with conventional medications for HF and ASV (ASV group) and 37 patients treated without ASV (Non-ASV group). BNP and LVEF were measured before and 6 months after treatment. Patients were followed for cardiac events after discharge. Results: In ASV group, BNP (P<0.01) and LVEF (P<0.01) significantly improved after 6 months. In contrast, these parameters did not change in Non-ASV group. Event free rate was significantly higher in ASV group (P<0.01). Conclusions: ASV improved cardiac function and prognosis in patients with HF and CSR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
